Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Outlicenses Products To California Startup, Considers Expanding Model To More Of Its Portfolio

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Astellas Pharma Inc. is trying out a new model, out-licensing three compounds to a startup created specifically to support the development of the products while Astellas retains options to buy back the products. The Japanese pharma is reducing costs for non-priority therapeutic targets, and if successful, may repeat the model for other compounds in its pipeline

You may also be interested in...



Astellas Shuts U.S./EU Phase III Diabetes Trial But Resumes Asia Development For Differentiated Markets

Astellas’ multi-track R&D approach leaves door open for a Western partner interested in a Phase III SGLT2 inhibitor, but the Japanese pharma’s main interest is finding ipragliflozin’s niche in Asia.

Astellas Shuts U.S./EU Phase III Trial But Resumes Asia Development For Differentiated Markets

Astellas’ multi-track R&D approach leaves door open for a western partner interested in a Phase III SGLT2 inhibitor, but the Japanese pharma’s main interest is finding ipragliflozin’s niche in Asia.

Japanese Firm Mitsui Invests In China's Hutchison MediPharma; First Step Toward An IPO?

SHANGHAI - Hutchison MediPharma, one of China's leading biotechs, announced Nov. 8 that Tokyo-based venture capital firm Mitsui had acquired a 12.2 percent stake in the company for $12.5 million, generating speculation among China watchers that it could be a first step toward self-funding and an eventual IPO for Hutchison

Related Content

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel